Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03446833 · ClinicalTrials.gov registry record · NA
LFP Beta aDBS Feasibility Study
A NA study, sponsored by MedtronicNeuro.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03446833: Clinical Trial NA study, sponsored by MedtronicNeuro.
NCT03446833 is a NA study that was terminated before completion, run by MedtronicNeuro. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03446833, a NA study, was terminated before completion, sponsored by MedtronicNeuro.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to use local field potentials as control signals for adjusting DBS stimulation settings under varying patient states and to assess patient outcomes.
Primary Outcome
To characterize the stimulation amplitude and LFP signals during execution of the Medtronic LFP -based aDBS adaptive algorithm. Descriptive statistics will be reported across different PD medication states and subject activities.
Interventions
- DEVICE The LFP Beta aDBS System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2019-02-06 |
| Phase | NA |
Why NCT03446833 stopped before completion
NCT03446833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which The LFP Beta aDBS System is the first listed.
NCT03446833 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03446833 about?
NCT03446833 is a clinical study titled "LFP Beta aDBS Feasibility Study". The purpose of this study is to use local field potentials as control signals for adjusting DBS stimulation settings under varying patient states and to assess patient outcomes.
What is the current status of trial NCT03446833?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2018-09-04. Estimated completion is 2019-02-06.
What interventions are being tested in trial NCT03446833?
The interventions under investigation include: The LFP Beta aDBS System (DEVICE).
Who is sponsoring clinical trial NCT03446833?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03446833's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI